Abstract:Background: Tigecycline, the first glycylcycline to be approved by the US Food and Drug Administration, is a structural analogue of minocycline that was designed to avoid tetracycline resistance mediated by ribosomal protection and drug efflux. It is indicated for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections and is available for intravenous administration only. Objective: This article summarizes the in vitro and in vivo activities and pharmacologic and pharmacokinetic properties of tigecycline, and reviews its clinical efficacy and tolerability profile. Methods: Relevant information was identified through a search of MEDLINE (1966-April 2006), Iowa Drug Information Service (1966-April 2006), and International Pharmaceutical Abstracts (1970-April 2006) using the terms tigecycline, GAR-936, and glycylcycline. Also consulted were abstracts and posters from meetings of the Infectious Diseases Society of America and the Interscience Conference on Antimicrobial Agents and Chemotherapy (1999-2006) and documents provided for formulary consideration by the US manufacturer of tigecycline. Results: Like the tetracyclines, tigecycline binds to the 30S subunit of bacterial ribosomes and inhibits protein synthesis by preventing the incorporation of amino acid residues into elongating peptide chains. In vitro, tigecycline exhibits activity against a wide range of clinically significant gram-positive and gram-negative bacteria, including multidrug-resistant strains (eg, oxacillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing Enterobacteriaceae), and anaerobes (eg, Bacteroides spp). In pharmacokinetic studies in human adults, tigecycline had a large Vd (7-9 L/kg), was moderately bound to plasma protein (71%-89%), had an elimination t(1/2) of 42.4 hours, and was eliminated primarily by biliary/fecal (59%) and renal (33%) excretion. Dose adjustment did not appear to be necessary based on age, sex, renal function, or mild to moderate hepatic impairment (Child-Pugh class A-B). In patients with severe hepatic impairment (Child-Pugh class C), the maintenance dose should be reduced by 50%. In 4 Phase III clinical trials in patients with complicated skin and skin-structure infections and complicated intra-abdominal infections, tigecycline was reported to be noninferior to its comparators (vancomycin + aztreonam in 2 studies and imipenem/cilastatin in 2 studies), with clinical cure rates among clinically evaluable patients of >80% (P < 0.001 for noninferiority). The most frequently reported (> or =5 %) adverse events with tigecycline were nausea (28.5%), vomiting (19.4%), diarrhea (11.6%), local IV-site reaction (8.2%), infection (6.7%), fever (6.3%), abdominal pain (6.0%), and headache (5.6%). The recommended dosage of tigecycline is 100 mg IV given as a loading dose, followed by 50 mg IV g12h for 5 to 14 days. Conclusions: In clinical trials, tigecycline was effective for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections. With the exception of gastrointestinal adverse events, tigecycline was generally well tolerated. With a broad spectrum of activity that includes multidrug-resistant gram-positive and gram-negative pathogens, tigecycline may be useful in the treatment of conditions caused by these pathogens.

A non-controlled, multicenter open-label study to evaluate the safety and efficacy of tigecycline in the treatment of infections secondary to burn injury

Salvage Tigecycline in High Risk Febrile Neutropenic Patients with Hematological Malignancies: a Prospective Multicenter Study.

High-dose Tigecycline for the Treatment of Nosocomial Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections A Retrospective Cohort Study

In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients

Tigecycline Salvage Therapy for Critically Ill Children with Multidrug-Resistant/extensively Drug-Resistant Infections after Surgery.

A Multicenter Clinical Trial of Piperacillin/tazobactam in Burn Infection

Efficacy and Safety of Tigecycline Monotherapy Vs. Imipenem/cilastatin in Chinese Patients with Complicated Intra-Abdominal Infections: a Randomized Controlled Trial

Effect of Piperacillin/tazobactam on Treating Traumatic Brain Injury with Pulmonary Infection: a Clinical Observation

A Multicenter, Double-Blind, Randomized, Comparison Study of the Efficacy and Safety of Tigecycline to Imipenem/cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects in China

Safety and effectiveness of tigecycline combination therapy in renal transplant patients with infection due to carbapenem-resistant gram-negative bacteria

Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections

Retrospective analysis of tigecycline shows that it may be an option for children with severe infections

Alternatives in monoclonal antibody production.

Preliminary Experience with Tigecycline Treatment for Severe Infection in Children

Unusual occurrence of six anti-erythrocyte alloantibodies in an Rh(D)-negative man with myelodysplastic syndrome.

Review of association between high-dose tigecycline and clinical outcome

Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections

Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia

Tigecycline: a glycylcycline antimicrobial agent

Effects of guanine bases at the central loop on stabilization of the quadruplex DNAs and their interactions with Meso-tetrakis(N-methylpyridium-4-yl)porphyrin.

Tigecycline-induced Acute Pancreatitis in a Renal Transplant Patient: a Case Report and Literature Review